Cargando…

Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy

We evaluated the predictive value of the ex-vivo PharmaFlow PM platform in measuring the pharmacological activity of drug combinations consisting of 20 different chemotherapy regimens (20 Tx) administered in 104 acute myeloid leukemia (AML) patients. The predicted sensitivities of alternative treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yi, Ji, Min, Zhao, Jin-Yan, Wang, Hua-Feng, Wang, Chong-Wu, Li, Wei, Ye, Jing-Jing, Lu, Fei, Lin, Li-Hui, Gao, Yan-Ting, Jin, Jie, Li, Li, Ji, Chun-Yan, Ballesteros, Joan, Zhu, Hong-Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767104/
https://www.ncbi.nlm.nih.gov/pubmed/35071002
http://dx.doi.org/10.3389/fonc.2021.793773
_version_ 1784634664036597760
author Zhang, Yi
Ji, Min
Zhao, Jin-Yan
Wang, Hua-Feng
Wang, Chong-Wu
Li, Wei
Ye, Jing-Jing
Lu, Fei
Lin, Li-Hui
Gao, Yan-Ting
Jin, Jie
Li, Li
Ji, Chun-Yan
Ballesteros, Joan
Zhu, Hong-Hu
author_facet Zhang, Yi
Ji, Min
Zhao, Jin-Yan
Wang, Hua-Feng
Wang, Chong-Wu
Li, Wei
Ye, Jing-Jing
Lu, Fei
Lin, Li-Hui
Gao, Yan-Ting
Jin, Jie
Li, Li
Ji, Chun-Yan
Ballesteros, Joan
Zhu, Hong-Hu
author_sort Zhang, Yi
collection PubMed
description We evaluated the predictive value of the ex-vivo PharmaFlow PM platform in measuring the pharmacological activity of drug combinations consisting of 20 different chemotherapy regimens (20 Tx) administered in 104 acute myeloid leukemia (AML) patients. The predicted sensitivities of alternative treatments for each patient were ranked in five 20% categories, from resistant to sensitive (Groups 1–5). The complete remission (CR) rates of the five groups were 0%, 12.5%, 38.5%, 50.0%, and 81.3%, respectively. The heat map showed a good relationship between drug sensitivity with CR (Group 4 + 5 vs. Group 1 + 2+3: 77.5% vs. 27.3%, p = 0.002) and the European Leukemia Net risk group (22.6% vs. 63.6%, p = 0.015). The predicted coincidence rate was 90.9% in Group 1 + 2 and 81.3% in Group 5. According to the recommendations of the PharmaFlow PM platform, the CR rate would have increased by about 16.3% in one cycle. The overall survival (OS) was shorter in patients predicted to be resistant (Group 1 + 2 vs. Group 3 + 4+5, p = 0.086). In multivariable analysis, CR after one cycle was an independent prognostic factor for OS [p = 0.001; 95% CI 0.202 (0.080–0.511)], and ex-vivo chemosensitivity was a potential predictive factor for OS [p = 0.078; 95% CI 0.696 (0.465–1.041)]. To conclude, the PharmaFlow PM platform is a rapid and valuable tool for predicting clinical response and outcomes in AML patients.
format Online
Article
Text
id pubmed-8767104
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87671042022-01-20 Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy Zhang, Yi Ji, Min Zhao, Jin-Yan Wang, Hua-Feng Wang, Chong-Wu Li, Wei Ye, Jing-Jing Lu, Fei Lin, Li-Hui Gao, Yan-Ting Jin, Jie Li, Li Ji, Chun-Yan Ballesteros, Joan Zhu, Hong-Hu Front Oncol Oncology We evaluated the predictive value of the ex-vivo PharmaFlow PM platform in measuring the pharmacological activity of drug combinations consisting of 20 different chemotherapy regimens (20 Tx) administered in 104 acute myeloid leukemia (AML) patients. The predicted sensitivities of alternative treatments for each patient were ranked in five 20% categories, from resistant to sensitive (Groups 1–5). The complete remission (CR) rates of the five groups were 0%, 12.5%, 38.5%, 50.0%, and 81.3%, respectively. The heat map showed a good relationship between drug sensitivity with CR (Group 4 + 5 vs. Group 1 + 2+3: 77.5% vs. 27.3%, p = 0.002) and the European Leukemia Net risk group (22.6% vs. 63.6%, p = 0.015). The predicted coincidence rate was 90.9% in Group 1 + 2 and 81.3% in Group 5. According to the recommendations of the PharmaFlow PM platform, the CR rate would have increased by about 16.3% in one cycle. The overall survival (OS) was shorter in patients predicted to be resistant (Group 1 + 2 vs. Group 3 + 4+5, p = 0.086). In multivariable analysis, CR after one cycle was an independent prognostic factor for OS [p = 0.001; 95% CI 0.202 (0.080–0.511)], and ex-vivo chemosensitivity was a potential predictive factor for OS [p = 0.078; 95% CI 0.696 (0.465–1.041)]. To conclude, the PharmaFlow PM platform is a rapid and valuable tool for predicting clinical response and outcomes in AML patients. Frontiers Media S.A. 2022-01-05 /pmc/articles/PMC8767104/ /pubmed/35071002 http://dx.doi.org/10.3389/fonc.2021.793773 Text en Copyright © 2022 Zhang, Ji, Zhao, Wang, Wang, Li, Ye, Lu, Lin, Gao, Jin, Li, Ji, Ballesteros and Zhu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Yi
Ji, Min
Zhao, Jin-Yan
Wang, Hua-Feng
Wang, Chong-Wu
Li, Wei
Ye, Jing-Jing
Lu, Fei
Lin, Li-Hui
Gao, Yan-Ting
Jin, Jie
Li, Li
Ji, Chun-Yan
Ballesteros, Joan
Zhu, Hong-Hu
Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy
title Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy
title_full Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy
title_fullStr Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy
title_full_unstemmed Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy
title_short Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy
title_sort ex vivo chemosensitivity profiling of acute myeloid leukemia and its correlation with clinical response and outcome to chemotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767104/
https://www.ncbi.nlm.nih.gov/pubmed/35071002
http://dx.doi.org/10.3389/fonc.2021.793773
work_keys_str_mv AT zhangyi exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT jimin exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT zhaojinyan exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT wanghuafeng exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT wangchongwu exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT liwei exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT yejingjing exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT lufei exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT linlihui exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT gaoyanting exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT jinjie exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT lili exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT jichunyan exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT ballesterosjoan exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy
AT zhuhonghu exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy